# A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)

> **NCT05632926** · PHASE2 · COMPLETED · sponsor: **Caliway Biopharmaceuticals Co., Ltd.** · enrollment: 12 (actual)

## Conditions studied

- Cellulite

## Interventions

- **DRUG:** 40 mg CBL-514
- **DRUG:** 60 mg CBL-514
- **DRUG:** 80 mg CBL-514

## Key facts

- **NCT ID:** NCT05632926
- **Lead sponsor:** Caliway Biopharmaceuticals Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-01-09
- **Primary completion:** 2023-05-03
- **Final completion:** 2023-05-03
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05632926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05632926, "A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With EFP; Cellulite (Stage 1)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05632926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*